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INTRODUCTION 
 
 Cardiovascular disease is the leading cause of morbidity and mortality in 
patients with CRF (Chronic renal failure) at all stages. Estimates of the increase 
in CVD (Cardiovascular disease) risk attributable to CRF range from 10 to 200 
fold depending on the stage of CRF, other risk factors and comorbid conditions. 
Between 30 to 45% of patients reaching ESRD (end stage renal disease), 
already have advanced cardiovascular complications. Thus the management of 
patients with CRF should emphasize prevention of cardiovascular 
complications as well as measures aimed at alleviating the progression and 
complications of CRF itself1.  
 
 It is obvious that ‘traditional risk factors, such as hypertension, chronic 
heart failure, dyslipidemia, tobacco smoking and diabetes mellitus may account 
for a large part of the increased cardiovascular mortality rate observed in these 
patients. However, based on recent research, it is evident that also other ‘non 
traditional’, risk factors such as, chronic inflammation, oxidative stress and 
malnutrition, may contribute to an increased cardiovascular mortality among 
dialysis patients5.    
 
 Traditional risk factors are inadequate as predictors of cardiovascular 
mortality in CRF patients. Even though diabetes mellitus and smoking were 
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strongly associated with CVD, neither serum total cholesterol nor systolic blood 
pressure was associated with coronary heart disease in these patients7. Hence it 
is prudent to look for other factors contributing to the morbidity and mortality 
in CRF patients. Recently CRP (C-reactive protein) has emerged as a more 
sensitive and specific indicator of an “acute phase” inflammatory metabolic 
response1. Our study tries to assess the correlation of hs CRP levels in CRF 
patients, particularly the CRF patients with cardiovascular complications.  
 
Assumption  
 
 The available western reports concluded an association between elevated 
CRP levels and cardiovascular morbidity and mortality among CRF cases. It is 
likely that hsCRP may be altered among the CRF patients of this area. However 
authenticated reports about this is lacking in this part of the country our 
presents study attempts to find out the same and its usefulness in clinical 
practice.       
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AIMS AND OBJECTIVES 
 
i. To estimate the hsCRP levels in newly detected chronic renal failure 
patients. 
  
ii. To identified variations in the hsCRP level among CRF patients with 
and without cardiovascular complications. 
 
iii. To find out the correlation between hsCRP levels and albuminuria, 
haemoglobin levels, retinopathy as well as cardiovascular 
complications among CRF patients.  
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REVIEW OF LITERATURE 
 
CRF  
 CRF is a progressive and significant reduction in glomerular filtration 
rate (GFR). This occurs gradually and the time period of its occurrence may 
vary from months to several years. The progression of renal failure ultimately 
leads to uremic syndrome which is defined as symptoms and signs associated 
with end-products of nitrogen metabolism. When GFR becomes less than 
5ml/min, CRF is very severe and will prove fatal unless renal replacement 
therapy is undertaken.10  
 
Aetiology  
 The aetiological spectrum of CRF differs somewhat in different parts of 
the world. Primary glomerulonephritis is the commonest cause of CRF in 
developing countries of the world whereas diabetic glomerulosclerosis is 
emerging as the most common cause of CRF in developed countries where life-
expectancy of diabetics has increased considerably as a result of better diabetic 
care.16  
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Important causes of CRF16 
A. Primary glomerulonephritis  
i. Proliferative  
ii. Focal glomerulosclerosis  
iii. Membranous 
iv. Membranoproliferative  
v. Cresentic   
 
B. Secondary glomerulopathy (systemic diseases) 
i. Diabetes mellitus  
ii. SLE 
iii. Amyloidosis  
iv. Vasculitis  
 
C. Interstitial renal diseases   
i. Chronic interstitial nephritis  
ii. Chronic pyelonephritis  
iii. Reflux nephropathy  
 
D. Hypertensive renal disease  
i. Nephrosclerosis  
ii. Renal artery stenosis  
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E. Obstructive nephropathy  
i. Urinary calculus  
ii. Prostatic enlargement  
iii. Tumours – kidney/bladder  
F. Heredo familial renal disease  
i. Autosomal dominant polycystic kidney disease  
ii. Medullary cystic disease  
iii. Alport’s syndrome 
Stages of CRF10 
Stage Description 
GFR ml/mt per 
1.73m2 
1 Kidney damage with normal or increased GFR 90 
2 Kidney damage with mildly decreased GFR 60-89 
3 Moderately decreased GFR 30-59 
4 Severely decreased GFR 15-29 
5 Renal failure  <15(or dialysis) 
  
Pathophysiology of uremia  
 The pathophysiology of uremic syndrome can be divided into two sets of 
abnormalities:  
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i. Those consequent to the accumulation of products of protein 
metabolism.  
ii. Those consequent to the loss of renal functions, such as fluid and 
electrolyte homeostasis and hormonal abnormalities.  
 
Uremia may contribute to some of the clinical features like anorexia, 
malaise, vomiting and headache. In addition to urea, excretion of additional 
categories of nitrogenous excretory products which are affected are quanido 
compounds, urates and hippurates, end products of nucleic acid metabolism, 
polyamines, myoinositol, phenols, benzoates and indoles.  
 
Nitrogenous compounds with a molecular mass of 500 to 12,000 Da (so 
called “middle” molecules) are also retained in CRF, contributing to morbidity 
and mortality.   
 
A host of metabolic and endocrine functions normally subserved by the 
kidney are also impaired, resulting in (a) anaemia, (b) malnutrition (c) impaired 
metabolism of carbohydrates fats and proteins; (d) metabolic bone disease.   
 
Cardiovascular and pulmonary disturbances in CRF  
1. Arterial hypertension  
2. CCF or pulmonary oedema 
3. Accelerated atherosclerosis  
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4. Pericarditis  
5. Cardiomyopathy  
6. Uremic lung 
7. Arrhythmias  
8. Vascular calcification 
9. Anaemia (indirectly worsens CVD)  
 
Symptoms and signs with CRF16  
A. General  
i. Oedema  
ii. Pallor  
iii. Malnutrition  
B. Gastrointestinal  
i. Anorexia  
ii. Nausea / Vomiting  
iii. Stomatitis  
iv. Gastritis  
v. GI bleeding  
 
C. Cardiovascular  
i. Hypertension 
ii. Pericarditis  
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iii. Cardiomyopathy   
iv. Congestive heart failure  
 
D. Neurological  
i. Peripheral neuropathy  
ii. Lack of mental alertness 
iii. Encephalopathy  
iv. Asterixis  
v. Convulsions  
E. Musculoskeletal  
i. Renal osteodystrophy (Bone pains) 
ii. Myopathy (Muscular weakness) 
F. Haemopoietic  
i. Anaemia  
ii. Bleeding and coagulation defects 
G. Pulmonary complications   
Pulmonary infections; TB 
H. Skin (Pruritus) 
 
Cardiovascular Abnormalities in CRF10 
 Hypertension is a particularly common cause and consequence of CRD 
(chronic renal disease), CRF especially in the elderly. It should be noted that 
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cardiovascular morbidity and mortality precludes most patients with CRF from 
reaching the stage of ESRD (End stage renal disease). Identification of CRF as 
a major risk factor for cardiovascular morbidity and mortality and the 
expectation of effective interventions to diminish premature cardiovascular 
mortality and increasing longevity overall, will increase the cohort of patients 
reaching ESRD.  
 
A. Ischaemic cardiovascular disease  
 CRF at all stages constitutes a major risk factor for ischaemic 
cardiovascular disease, including occlusive coronary heart disease, 
cerebrovascular disease and peripheral vascular diseases. Increased prevalence 
of coronary heart disease in CRF derives from both traditional (“classic”) and 
CRF related (“non traditional”) risk factors. 
 The CRF related risk factors include: 
i. Anaemia  
ii. Hyperphosphatemia  
iii. Hyperparathyroidism  
iv. Microinflammation (which is found in all stages of CRF 
but is undoubtedly aggravated by dialysis).  
 
The inflammatory state elicits a rise in acute phase reactants such as IL-6 
and C-RP, which contribute to the coronary occlusive process and are 
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predictors of CVD (cardio vascular disease) risk. Other abnormalities augment 
myocardial ischaemia. These include reduced myocardial tolerance to 
ischaemia due to LVH (left ventricular hypertrophy) and microvascular disease. 
Also coronary reserve (defined as the increase in coronary blood flow in 
response to greater demand) is attenuated. Nitric oxide, an important mediator 
of vasodilatation is reduced in CRF even at early stages of CRF, and also 
because nitric oxide is scavenged by reactive oxygen species. In addition, 
coronary arteriolar hypertrophy / hyperplasia limits vascular capacity.  
 
B. Congestive heart failure  
    Congestive heart failure and / or pulmonary oedema in uremia can be 
due to  
(i) Abnormal cardiac function secondary to myocardial 
ischaemia.  
(ii) LVH 
(iii) Salt and water retention  
(iv) Uremic lung  
 
A unique form of pulmonary congestion and oedema may occur even in 
the absence of volume overload and is associated with normal or mildly 
elevated intracardiac and pulmonary capillary wedge pressure. This entity is 
characterized radiologically by peripheral vascular congestion giving rise to a 
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“butterfly wing” distribution, is due to increased permeability of alveolar 
capillary membranes. This “low pressure” pulmonary oedema as well as 
cardiopulmonary abnormalities associated with circulatory overload, usually 
respond promptly to vigorous dialysis.  
 
C. Hypertension and left ventricular hypertrophy (LVH) 
 Hypertension is the most common complication of CRF and ESRD. It 
may develop early during the course of CRF and is associated with adverse 
outcomes – in particular, more rapid loss of renal function and development of 
CVD. Numerous epidemiological studies and clinical trials have shown a 
relationship between the level of blood pressure and the rate of progression 
diabetic and non diabetic kidney disease.  
 
 Administration of EPO (Erythropoietin) may raise blood pressure and 
increase the requirement for antihypertensive drugs in CRF patients. Left 
ventricular hypertrophy and dilated cardiomyopathy are among the most 
ominous risk factors for excess cardiovascular morbidity and mortality in 
patients with CRF and ESRD and are thought to be related primarily to 
prolonged hypertension and extracellular fluid volume overload. In addition 
anaemia and the surgical placement of an AV fistula for future / ongoing 
dialysis access may generate a high cardiac output state and pulmonary 
hypertension which also intensify the burden placed on left ventricle.  
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 Since volume overload is the major cause of hypertension in uremia the 
normotensive state can be restored by appropriate use of salt restriction or 
natriuretic drugs are ultrafiltration in the dialysis setting. Neverthless, because 
of hyperreninemia and other disturbances in renal vasoconstrictors and 
vasodilators some patients remain hypertensive despite rigorous salt and water 
restriction and ultrafiltration. 
 
D. Pericarditis and Pericardial Effusion 
 Pericardial pain with respiratory accentuation by a friction rub, are the 
hallmarks of uremic pericarditis. The finding of the multi component friction 
rub strongly supports the diagnosis.  
 
 Pericarditis may be accompanied by the accumulation of pericardial fluid 
that is readily detected by echocardiography, that sometimes leads to cardiac 
tamponade. Pericardial fluid in uremic pericarditis is more often heamorrhagic 
than in viral pericarditis.            
 
E. Anaemia16  
 Anaemia in CRF is due to several factors such as: 
i. Chronic blood loss  
ii. Haemolysis  
iii. Bone marrow suppression by retained uremic factors 
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iv. Reduced renal production of EPO  
v. Secondary hyperparathyroidism  
 
  The degree of anaemia in CRF parallels roughly the degree of renal 
failure3. Decreased EPO production by the diseased kidneys seems to be the 
main mechanism of renal anaemia but other factors such as inhibitors of EPO 
and deficiency of haemopoietic nutrients like folic acid and iron may contribute 
to anaemia in CRF.  
 
Untreated anaemia leads to left ventricular hypertrophy which increases 
the risk of sudden death16.  
 
Conditions associated with major elevations of CRP20  
 Tissue damaging processes, infections, inflammatory diseases of 
unknown etiology and malignant neoplasms are associated with major acute 
phase response of CRP. CRP levels reflect quite precisely the extent and 
activity of the disease.  
 
Conditions with elevated CRP 
A. Infections  
i. Most systemic microbial infections 
ii. Systemic fungal infections  
iii. Chronic bacterial infections  
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iv. Malaria, especially falciparum malaria (high CRP) 
v. Pneumocystis, toxoplasma infection  
B. Chronic inflammatory diseases  
i. Rheumatoid arthritis  
ii. Ankylosing spondylitis  
iii. Proriactic arthritis  
iv. Systemic vascultis  
v. Reiter’s disease  
vi. Crohn’s disease  
 
 In diseases with pathology relatively inaccessible to direct examination, 
eg: systemic vasculitis, Crohn’s disease etc., CRP estimation provides best 
available objective index of disease activity.   
 
C. Tissue necrosis  
i. Myocardial infarctin  
ii. Tumor embolisation  
iii. Acute pancreatitis  
[Stable angina and coronary arteriography do not stimulate CRP 
production]. 
D. Trauma  
i. Surgery  
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ii. Burns  
iii. Fractures  
E. Malignancy  
i. Lymphoma  
ii. Hodgkin’s disease  
iii. Carcinoma  
iv. Sarcoma  
 
C - Reactive Protein (CRP)20 
 CRP is an acute phase reactant synthesized in liver. If belongs to a 
family of soluble proteins called pentraxins (radial pentameric structure). Their 
production is induced by inflammatory cytokines like IL1 & IL 6 (interleukins), 
and they are able to activate the classical pathway of complement by directly 
binding to complement C1q.  
 
 CRP was named for its calcium dependent interaction with somatic C-
polysaccharide of pneumococci.  
 
 Liver makes huge quantities of CRP and serum amyloid associated 
protein which are not found at all in normal serum2. In 24 hours, the liver can 
synthesize about 15 grams of CRP. The response persists in individuals with 
chronic infections, chronic inflammation or invasive / metastatic neoplasms and 
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is sustained.  CRP through its capacity to activate complement, can exacerbate 
ischaemic and possibly also other forms of tissue damage.  
 CRP molecule consists of five identical nonglycosylated, polypeptiole 
subunits each of mass 23027 Daltons and containing 206 aminoacid residues 
arranged in annular configuration with cyclic pentameric symmetry2. 
 
Functions of CRP20  
i. It recognizes and ‘scavenges’ cellular debris and promotes its 
clearance. 
ii. Protects against infection with pneumococci and H. Influenza. 
iii. Complement activation by CRP exacerbates ischaemic injury. 
iv. It is proatherogenic – by binding to phospholipids and lipoproteins. 
v. It is prothrombotic – CRP stimulates tissue factor production by 
macrophages. 
vi. CRP suppresses polymorph migration (which is anti-inflammatory). 
 
Serum concentration  
 CRP is a trace protein in normal healthy individual.  
Median value is 0.08mg/dL (0.8mg/L). 
Normal range is 0.03 mg/dL to 0.17 mg/dL20 . 
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The half life of CRP in circulation is 19 hours and is constant in all 
conditions regardless of the presence of acute phase response or its cause. The 
speed of change and incremental range of CRP concentration are exceptional 
among all acute phase reactants. The single major determinant of the circulating 
concentration of CRP is its rate of synthesis; hence serum CRP level usually 
closely reflects the extent and activity of disease. Drug or other treatments do 
not affect CRP production unless they affect the disease process. The only 
physical condition which interferes with the capacity to interpret CRP levels is 
serious hepato-cellular impairment.  
 
CRP as cardiovascular risk predictor3  
 The American Heart Association and the centre for Disease Control and 
prevention has recently issued guidelines for the use of hs CRP in clinical 
practice.  
h.s. CRP level  Cardiovascular risk  
<0.10mg/dL (<1mg/L) Low risk 
0.10 mg/dL to 0.3mg/dL (1 to 3 mg/L) Moderate risk 
>0.3mg/dL (>3mg/L) High risk 
 
 In primary prevention, a large series of prospective of epidemiological 
studies has convincingly demonstrated that CRP, when measured with high 
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sensitivity assays (hs-crp), strongly and independently predicts risk of 
myocardial infarction, stroke, peripheral arterial diseases and sudden cardiac 
death even a among apparently healthy individuals. These data apply to women 
as well as to men across all age levels.   
 
 CRP is not only a marker of inflammation, but also may influence 
vascular vulnerability through several mechanisms like:  
 
i. Enhanced expression of local adhesion molecules 
ii. Increased expression of endothelial plasminogen activator inhibitor  
iii. Reduced nitric oxide bioavailability  
iv. Altered LDL uptake by macrophages, and  
v. Colocalization with  complement within atherosclerotic lesions 
 
Consistently high values of CRP represent very high risk of future 
cardiovascular disease because risk appears linear across the full range of CRP.  
 
Advantages in hs-CRP screening20 
i. CRP levels are stable over long period of time  
ii. Have no circadian variation  
iii. Not affected by food intake, and  
iv. Screening can be done on an outpatient basis 
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Strong evidence shows that hs-CRP adds prognostic information at all 
levels of LDL cholesterol, at all levels of the Framingham risk score, and at all 
levels of the metabolic syndrome.  
 
Of the commercially available predictors for cardiovascular risk hs-CRP 
has the greatest magnitude of prediction value. Further hs CRP adds important 
prognostic information to global risk prediction.  
 
CRP evaluation will likely become a routine part of coronary risk 
prediction.  
Reliability of CRP and ESR20? 
   The only other comparable non-specific index of the presence of disease 
which is routinely measured is the ESR. The ESR reflects, in part, the intensity 
of the acute phase response, especially that of fibrinogen and the α-globulins, 
but is also largely determined by the concentration of immunoglobulins, which 
are not acute phase reactants. These proteins have half-lives of days to weeks. 
The rate of change of ESR is thus very much slower than that of the CRP level, 
and it rarely reflects precisely the clinical status of the patient at the actual time 
of testing. ESR is also dependant on the number and morphology of the red 
cells, which bear no relation to the acute phase response. Finally there is 
significant diurnal variation in ESR, depending on food intake, which is not 
seen in CRP. 
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 The ESR is therefore of limited use as an objective index. The dynamic 
range of the ESR is also much less than that of CRP and the precision and 
reproducibility of ESR measurement is poor compared to robust immunoassays 
for CRP. Thus in all clinical situations, frequent prospective measurement of 
CRP reflect disease activity very much more closely than ESR. Finally ESR 
does not provide the information given by the high sensitivity measurement of 
CRP. ESR remains a useful screening test for the detection of paraproteinemias, 
especially multiple myeloma, which do not necessarily provoke an active phase 
response.    
 
Association of CRP in CRF patients in recent studies  
 
Stevinkel28 et al 2000; In their review article, conclude that chronic 
inflammation, as evidenced by increased levels of various acute phase reactants 
such as CRP, fibrinogen, serum amyloid A (SAA), transferring, albumin and 
prealbumin is a common feature in dialysis (CRF) patients.  
 
 The inflammation may rather be a marker of an atherogenic milieu and 
inflammation has been proved to be associated with endothelial dysfunction, 
insulin resistance and oxidative stress, all of which may accelerate 
atherosclerosis.  
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 A number of ‘non traditional’ risk factors for CVD such as 
hyperhomocysteinemia, oxidative stress, vascular calcification, malnutrition 
and inflammation are commonly found in CRF patients. They provide a 
rationale for the remarkable prevalence of atherosclerotic CVD in these 
patients.  
 
 Further the author says that in their prospective study, they have found 
that various markers of malnutrition and inflammation are strong independent 
predictors of mortality in dialysis patients.  
 
 Mechanisms by which various acute phase reactants may cause 
atherosclerotic CVD.  
a. Possible “direct” mechanisms  
i. CRP deposition in the arterial wall  
ii. CRP causes direct tissue damage  
iii. SAA affects lipoprotein structure  
iv. Lp-a, promotes athero – and thrombogenesis  
v. Fibrinogen promotes athero and thrombogenesis and increases 
plasma viscosity.   
b. Possible “indirect’ mechanisms 
i. Endothelial dysfunction eg: reduced nitric oxide  
ii. Insulin resistance   
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iii. Increased oxidative stress  
iv. Stimulation of AGEs (advanced glycation end products) 
v. Persistent atherogenic infections eg. C. Pneumoniae, H.pylori  
 
Stenvinkel28, et al 2000; In their study propose two types of malnutrition 
in CRF patients, type 1: associated with uremic syndrome per se and type 2: 
cytokine – driven type of malnutrition. The proposed features are:  
    Type 1       Type 2 
i. Serum albumin   Normal /low Low 
ii. Co-morbidity Uncommon Common 
iii. Presence of inflammation No Yes  
iv. Food intake Low Low/normal 
v. Resting energy expenditure Normal Elevated  
vi. Oxidative stress Increased Markedly increased 
vii. Protein catabolism Decreased Increased  
viii. Reversal by dialysis and 
nutritional support 
Yes No 
 
Their study recognized that about 30-50% of predialysis, HD and PD 
patients had serologic evidence of an activated inflammatory response as 
evidence by elevated CRP levels29,33,31.  
 
The proposed potential causes of inflammation in patients with CRF are:  
i. Reduced renal clearance of cytokines  
ii. Reduced renal clearance of AGEs 
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iii. Chronic heart failure 
iv. The atherosclerotic process per se  
v. Various inflammatory diseases  
vi. Unrecognized persistent infections eg. C.pneumoniae, H.pylori   
 
In a study Kimmel11 et al, 1998; reported the generation of pro-
inflammatory cytokines (IL-1, IL-6 and TNFα) which have been markedly 
elevated in CRF patients and predicts the mortality. Serum levels of CRP 
appears to reflect the generation of such cytokines.  
 
In a study Heinrich8 et al, 1995; suggested that, by virtue of its acute 
phase behaviour the CRP may be a marker for severity and progression of 
atherosclerotic processes in the vessels12.  
 
They also showed that elevated CRP can predict cardiovascular 
mortality.  
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MATERIALS AND METHODS 
 
Setting    : This work was done at 
Government Rajaji Hospital, affiliated to the  
Madurai Medical College, Madurai.  
 
Collaborating Department: Department of Medicine in collaboration  
     with departments of Nephrology and  
     Cardiology. 
 
Design of study   : Cross sectional and analytical study.  
 
Period of study   : January 2005 to February 2006.  
 
Ethical approval  : Approval for the study was obtained from the 
ethical committee of Government Rajaji 
Hospital, Madurai.  
Consent   :  Prior informed consent was obtained from all 
the cases and controls included in the study.  
 
Sample size    : 42 newly detected CRF patients.   
     10 controls (normal individuals) 
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Selection of study subjects: (Cases and Controls) 
  Cases   : Newly detected CRF patients admitted to  
Govt. Rajaji Hospital, who satisfied the 
inclusion criteria were selected for the study.  
  Controls  : Age and sex matched healthy volunteers  
were selected after getting consent.  
 
Inclusion criteria  
i. Elevated blood urea levels  
ii. Elevated serum Creatinine levels  
iii. Ultrasound abdomen – medical renal disease  
Exclusion criteria  
i. Diabetes mellitus  
ii. Previous history of IHD 
iii. Acute / chronic liver diseases 
iv. Rheumatoid arthritis  
v. Documented connective tissue disorders  
vi. Previously diagnosed renal failure patients  
vii. Surgical causes of CRF (obstructive uropathies) / trauma 
viii. Smokers  
ix. Fever within 1 week prior to admission  
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x. Skin infections / any other overt infections    
xi. Malignancy  
xii. Children  
xiii. Pregnant women  
xiv. Immunosuppressive drug therapy  
Socio demographic data  
 Age  
 Sex  
 Socio demographic and clinical data were collected. The study 
subjects were subjected to relevant investigations. 
Clinical details  
• Anaemia was identified.  
• Systolic and diastolic blood pressures were measured.   
• General and Systemic examination was done. 
• Cardiovascular risk factors were assessed. 
• Fundus examination was done.     
Laboratory data  
• Total and differential count of WBCs was done.  
• Hb in gm% was estimated by Sahli’s method. 
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• Urine albumin was estimated using standard dipsticks.(semi 
quantitative method) 
• Blood urea estimation was done manually by using diacetyl 
monoxime (DAM) method.  
• Serum creatinine estimation was done by using COBAS auto 
analyser 
• Serum hs CRP estimation was done by Nephalometry method 
• ECG 12 lead Electro Cardio Gram was done.(Philips) 
• ECHO – Echo Cardio Graphic evaluation was done 
• Ultra sono gram abdomen. 
 
Definitions used for this study 
1. Anaemia – Hb level below 10gm/dL (marked anaemia) [Sood S.K, 
U.Rusia, Ann of Nat. Acad. of Med. Sci, India, 1986; 22(4): 235.  
 
2. CRF – is a pathophysiologic process resulting in the attrition of nephron 
number and function and frequently leading to end-stage-renal disease 
(ESRD) [Loss of cortico medullary distinction by ultra sono gram] 
3. LVH – ECG findings – based on Sokolon-Lyon criteria [Sokolon, Lyon 
1949, Casale et al 1987].  
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4. Hypertensive Retinopathy (Grading) – based on Keith-Wagener-Baker 
classification of funduscopic changes.  
5. Cardio vascular complications – left ventricular hypertrophy ishchaemic 
changes LV dysfunction, Pericardial effusion 
Procedure for data collection  
There were about 272 CRF patients diagnosed during the study period, 
of whom more than 65% were found to be diabetics. 13% were IHD patients. 
After applying strict selection criteria and getting consent only 42 patients 
(28males and 14females) were selected for this study. The patients initially 
underwent clinical evaluation and routine laboratory tests and were subjected to 
ultrasound examination of abdomen. 
  
After diagnosis of CRF, the patients were subjected to ophthalmologic 
evaluation to study hypertensive retinopathy. ECG was taken for all the patients 
and then echocardiographic evaluation was done for them.  
 
 Blood samples were collected from the patients after over night fasting 
and one time estimation of hs – CRP was done by nephalometry method. 
 
Limitations of this study 
1. CRF patients with comorbid conditions, though common were not 
included for this study.  
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2. The lower limit of the hs CRP estimation by (Nephalometry 
method) laboratory was 0.10mg/dL. [below which it may not be 
accurate]. 
3. Hypertension could be the cause or the consequence of CRF.    
4. Serial estimation of hs CRP was not done in this study. 
Financial support :  Nil  
Conflicting interest : Nil  
Statistical analysis  :   
Data was method in Microsoft excel spirit sheet. Analysis of data was 
done utilizing the software - Epidemiological Information Package 2002 (Epi 
info 2002) developed by the Centers for Disease Control and Prevention-
Atlanta, USA for World Health Organization. Mean standard deviation and ‘p’ 
values were calculated using this package. Chi Square test was done were ever 
necessary to find out significance of relationship between both groups. Since 
the variances were not homogenous, KRUSKUL-WALLY'S TEST (X2 test) 
was used to find out the significance of difference. 
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RESULTS 
In the present study 42 cases of CRF satisfied rigid selection criteria. Their age 
ranged from 23 years to 67 years and the mean ± S.D. was 48.6 ± 10.3 years. 
The distribution of cases in relation to age group is provided in table no.1 given 
below. 
Table 1: Distribution of study subjects with relation to AGE 
 
Study Cases Control Cases Age Group 
(years) No % No % 
< 30 2 4.8 2 20 
31-40 7 16.7 2 20 
41-50 14 33.3 2 20 
51-60 15 35.7 2 20 
> 60 4 9.5 2 20 
Total 42 100 10 100 
Mean 48.6 44.9 
S.D. 10.3 15.9 
    'p' = 0.4857 ( Not significant ) 
 
 
 The mean age for the study population was 48.6 with S.D of ± 10.3 years 
 The mean age for the control group was 44.9 with S.D of ±15.9 years 
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Among the CRF patients in this study 29 patients (69%) were found to be in the 
age group between 40 to 60 years. 
*The patients did not differ statistically from the control with reference to 
age. 
Figure : 1 
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In our study there were 28 male CRF patients and 14 Females CRF 
patients; the control group consisted of 5 males and 5 females.  Details are 
provided in table .2 and figure 2. 
Table 2: Distribution of study subjects with reference to gender: 
Study Cases Control Cases Total 
Gender 
No % No % No % 
Males 28 66.7 5 50 33 78.6 
Females 14 33.3 5 50 19 21.4 
   'p' = 0.2647 ( Not significant ) 
 There was no statistical difference as for as the gender status of the 
study and control group. 
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Details of selected characteristics of the study group is given below: 
 
Table 3 : PARAMETERS 
 
Study Controls 
Parameters 
Range Mean S.D Range  Mean S.D 
Blood sugar 
mg% 
68-126 101.5 15.8 96-120 109.4 806 
Urea mg% 68-252 143.8 46.1 30-38 35.3 2.8 
Sr.Creatinine 
mg% 
2.2-13.8 6.5 2.83 0.8-1.1 0.93 0.12 
Hb. Gm% 5.2-10.9 8.75 1.31 13.0-14.2 13.6 0.4 
C.R.P mg% 0.10-3.02 1.22 0.99 0.07-1.1 0.08 0.01 
Sys. B.P mmHg 1.10-2.40 16507 23.8 100-130 119 9.9 
Dias. B.P. 
mmHg 
70-140 104 13.3 70-86 77.2 5.5 
 
  
The hs CRP levels in the study group were significantly elevated when 
compared to the control group. (continued)  
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  Study group – Mean – 1.22 md/dl (12.2 mg/l) with S.D. of ± 0.99 
 The control group - Mean – 0.08 mg/dl (0.8 mg/l)with a S.D. of ± 0.01 
 The mean Hb% in this study group was 8.75 gm% with S.D. of ± 1.31 
gm%  which was significantly lower than the control group – (13.6 gm% S.D. 
of ± 0.4).    
During our study there was no mortality. 
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Table 4: MEAN CRP LEVELS IN CASES AND CONTROLS 
 
 The CRP level varied from 0.10 – 3.02mg% in the study group whereas 
in the control group it varied from 0.07 – 1.1mg%. 
 
 The Mean and SD among the study group is given below 
 
 
CRP Levels (mg /dl) 
 
Range  Mean S.D. 'p' value Significance 
Cases 0.10 – 3.02 1.22 0.99 
Controls 0.07 – 1.1 0.08 0.01 
0.0001 Significant 
 
 
 The mean CRP level in the study group was 1.22mg% with SD of ± 
0.99. 
 The mean CRP level in the control group was 0.08 (<0.10) with SD of ± 
0.01. 
 This was statistically significant. It was also found the CRP level was 
independent of serum creatinine.  
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Table 5 : RETINOPATHY  
 
Study 
Without 
CVD  
With  
CVD Retinopathy 
No % NO % No % 
Normal 1 2.4 1 6.7 0 - 
Grade I 3 7.1 2 13.3 1 3.7 
Grade II 24 57.1 10 66.7 14 51.9 
Grade III 14 33.3 2 13.3 12 44.4 
 
  
In our study about 24 patients (57.1%) were suffering from Grade – II 
retinopathy and 14 patients (33.3%) were suffering Grade – III retinopathy at 
the time of admission. 
 
 This was statistically significant. 
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Table 6: RETINOPATHY AND MEAN  CRP LEVELS IN CASES  
 
CRP Levels 
Retinopathy 
Mean S.D. 'p' value Significance 
Normal 0.14 - 
Grade I 0.65 0.8 
Grade II 1.14 0.98 
Grade III 1.56 1.01 
 
0.0001 
 
Significant 
 
 The CRP levels correlated positively with the severity of retinopathy in 
CRF patients and it was statistically significant.   
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Table 7: Anaemia (Moderate to severe - <10gms%)  
 
Study Controls Hb % 
 No % No % 
'p' 
value 
Significance 
14.3 10 100 0.0001 Significant 
dL with SD of ± 0.45.  The statistical analysis was very much significant                
(p - 0.0001).    
 
  
 
 
 
 
DISCUSSION 
 
 Despite the recent considerable improvements in Renal replacement 
therapy, cardiovascular disease still remains the main cause of morbidity and 
mortality in CRF patients10. It is evident from recent studies [(Lidner15, et al 
(1974); Stenvinkel29, et al (1999); and Cheung5, et al (2000)]; that the 
atherosclerotic process is accelerated in CRF patients. A number of ‘non 
traditional’ risk factors for CVD, such as homocysteinemia, oxidative stress, 
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vascular calcification, malnutrition and inflammation are commonly found in 
CRF patients2.  
 
 Evidence from experimental and clinical studies has shown that 
inflammation in general, and CRP specifically, may contribute directly to 
pathogenesis of atherosclerosis and its complications both in general 
community and in patients with CRF20.  
 
 Recent studies [Zimmermann33, et al, Yeun31, et al, Owen18, et al and 
Yeun, Kaysen] recognized  that about 30-50% of predialysis, HD and PD 
(CRF) patients suffered from CVD and they had elevated CRP levels.   
 In the present study that the mean hsCRP level was 1.22 mg/dL in CRF 
patients which was significantly higher than the mean CRP level of the control 
group 0.08 mg/dL (<0.10mg%). The mean CRP level of 1.22mg/dL in our CRF 
patients was definitely higher than the reference value of 0.3mg/dL for high 
cardiovascular risk (American Heart Association guidelines)19.   
 Elevated CRP as an independent risk factor for cardiovascular disorders 
was confirmed by various authors [Ridker22, et al (2002); Pradhan21, et al 
(2002); and Albert1, et al (2002)]. It was applicable to both men and women and 
across all age levels as well as to diverse populations. Elevated CRP levels in 
the present study was independent of age and gender. Thus the present 
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observation of elevated hsCRP levels in CRF patients concurred with early 
published report.   
 
 The most significant process that correlates with inflammation is 
atherosclerotic CVD as evidenced by elevated CRP. Recent studies have 
established that the levels of proinflammatory cytokines such as IL-6 or acute 
phaseproteins like CRP predict CVD (Ridker23, et al, 1997). 
 
 Heinrich8, et al (1995) concluded in their study that, CRP may be a 
marker for severity and progression of atherosclerotic processes in the vessels. 
In the present study out of the 42 CRF cases 24 (57.1% were suffering from  
grade II retinopathy and 14 patients (33.3%) were suffering from Grade III 
retinopathy. This was statistically very much significant compared to the 
control group. Also, the CRP levels in CRF patients correlated positively with 
the severity (Grade) of retinopathy. The mean CRP level for patients with 
Grade II retinopathy was 1.14mg/dL and for Grade III 1.56mg/dL. In view of 
significantly elevated CRP levels in patients with CRF, and its correlation with 
increasing severity in retinopathy it is likely that it is a marker for ongoing 
vessel changes.      
Echocardiographic findings in the CRF patients of our study  
  In the present study the echocardiographic evaluation revealed that out 
of the 42 CRF patients only 15 had normal cardiac function and 27 patients 
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(64.3%) had cardiovascular abnormalities in the form of left ventricular 
hypertrophy, ischaemic changes (hypokinesia of wall/septum) LV dysfunction 
and pericardial effusion. The mean CRP level in CRF patients without CVD 
was 0.18 mg/dL whereas for CRF patients with CVD was 1.96 mg/dL which 
was significantly higher. An association between elevated CRP and CVD were 
shown by earlier workers from different parts of the world (Stenvinkel29, et al 
1999). In a recent updated metaanaylsis including 2,557 cases, Danesh6, et al 
2000, reported that the combined risk ratio for coronary heart disease was 1.9 
times higher in the patients who had the highest CRP. Elevated CRP has been 
shown to predict cardiovascular mortality by (Yeun32, et al 2000; 
Zimmermann33, et al 1999). The same conclusion was given by Bergstorn2, et al 
1995 and Iseki9, et al 1999.      
 
 
 Anaemia is commonly seen in CRF and its severity parallels roughly 
with the degree of renal failure16. Similar observations were made among CRF 
patient of the present study. It was found that 36 of the 42 CRF (85.7%) 
patients suffered from anaemia, which was statistically significant. The mean 
hsCRP levels of this anaemic CRF patients was 1.39mg/dL which was very 
high (8 times higher) than the mean hsCRP level of 0.18mg/dL in CRF patients 
without anaemia. The severity of anaemia indirectly correlated with the severity 
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of CRF. Interestingly it is to be noted here that anaemia per se does not 
influence CRP levels3. 
 
An attempt was made to find out whether any association exists between 
severity of albuminuria and serum levels of hs-CRP. In the present study 
severity of albuminuria (semiquantitative method) showed direct relation to 
severity of CRF. Of the 42 patients 20 had albuminuria of 1+, 17 had 2+ and 3 
had 3+. The prevalence of albuminuria was (95.2%) in the CRP patients. And 
the mean CRP levels showed a linear relation with the degree of proteinuria, 
indirectly implicating the severity of CRF.   
 The present study brought out significantly elevated hsCRP levels in 
cases of CRF and association between hsCRP and albuminuria, anaemia, 
retinopathy and cardiovascular complications, which were supported by an 
array of published literature from different parts of the world. Time has come to 
consider whether any infective etiology could contribute for the onset and 
worsening of chronic kidney disease.  
 The areas for future research are suggested below; 
1. Usefulness of antimicrobial therapy to arrest or delay the 
progression of CRF. 
2. To identify how frequently to estimate hsCRP levels in 
CRF patients. 
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3. The identification of newer pathogenic organisms as 
contributory factors for the development of cryptogenic 
CRF.  
        
 
 
 
 
 
 
   
 
 
 
CONCLUSIONS 
 
• The hsCRP levels among CRF patients was independent of age, 
gender or serum creatomy levels. 
• The hsCRP levels was significantly elevated in CRF patients (Range 
0.10 – 3.02mg%, mean 1.22mg% with SD ± 0.99mg%) when 
 45
compared to healthy controls (Range 0.07 – 1.1mg% mean 0.08 with 
SD ± 0.01). 
• The hsCRP levels were elevated significantly in those CRF patients 
with cardiovascular complications (Range 0.13 – 3.02mg% mean 
1.96 with SD of ± 0.45mg%) when compared with those without 
cardiovascular complications (Range 0.10 – 0.3mg% mean 0.18 with 
SD of ± 0.06mg%) there by indicating that elevated hsCRP is a 
marker of development of cardiovascular morbidity. 
• The present study has brought out an association between elevated 
hsCRP and degree of albuminuria, haemoglobin levels, severity of 
retinopathy as well as cardiovascular morbidity. 
• Areas for futures research and recommendations were identified.              
 
 
RECOMMENDATIONS / SUGGESTIONS 
  
Chronic renal failure is characterized by exceptionally high mortality 
rate, much of which is the result of cardiovascular disease. Recent studies 
demonstrate that chronic inflammation, as evidence by increased levels of pro-
inflammatory cytokines and CRP is a common feature in CRF patients.  
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At the time of diagnosing CRF in a patient, the clinician is at dark about 
the duration of the renal failure in the patient and his current morbidity status. 
When the clinician is at dilemma about which patient to choose for intensive 
therapy, the hs-CRP estimation gives the vital clue. It is the best single 
available parameter because of its stability and reproducibility over time and 
above all its ability to predict the prognosis.  
 
1. It is hereby suggested that hs-CRP estimation should be included in the 
routine evaluation of all CRF patients.  
 
2. CRF patients with elevated hsCRP should be adequately counseled 
regarding their proneness to develop cardiovascular complications. 
 
 
3. In this era of consumer litigations, hs-CRP estimation in CRF patients 
helps the clinician to boldly submit a patient with high CRP levels for 
extensive cardiac evaluation and to start necessary preventive measures 
/treatment.  
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4. CRF patients with elevated hsCRP require detailed cardiological 
workup and addition of therapeutic agents to prevent cardiovascular 
mortality and morbidity.  
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 In the present study a group of 42 newly detected CRF patients (28 
males and 14 females) were selected and 10 normal individuals (5 males and 5 
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females) were selected as control group after careful application of inclusion 
and exclusion criteria. They were subjected to detailed sociodemographic 
clinical and systemic examination and routine laboratory tests. The study 
subjects underwent ultrasonographic evaluation. A single time fasting blood 
sample was obtained and hs-CRP assay was done. Then they underwent 
funduscopic and echocardiographic evaluation. The results obtained were 
statistically analysed using Epi info-2002.  
 
 CRF patients are susceptible to cardiovascular morbidity and mortality. 
Various risk factors have been identified in them. One another risk factors was 
elevated hsCRP the present study has made an attempt to find out hsCRP levels 
in the selected CRF patients and correlate the levels with albuminuria, 
haemoglobin levels, severity of retinopathy and cardiovascular complications. 
 
 The hsCRP levels were significantly elevated in the CRF patients (Mean 
1.22mg% SD ± 0.99mg%) than the control (Mean 0.08mg% SD ± 0.01mg%) 
and it was independent of age, gender and serum creatinine levels. However 
elevated hsCRP correlated with albuminuria, haemoglobin levels, severity of 
retinopathy and cardiovascular morbidity. 
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 The hsCRP measurement may well prove an exception in view of its 
robustness, its relative stability in individuals over time, and most importantly 
its ability to add to the cardiovascular risk information. 
 
 Areas for future research and recommendation were identified.            
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MASTER CHART 
 
Sl. No.  
Case 
Control Age  Sex  
Blood 
Sugar  Urea Hb% Sr.Cr 
Retinopathy 
Gr CRP ECH Echo 
BP.(on 
Adm) 
Urine 
Alb 
1 CN 22 M 108 36 14 0.9 - 0.09 N N 110/70 - 
2 CN 24 F 112 38 13.6 0.8 - 0.09 N N 100/70 - 
3 CN 45 M 98 30 13.4 0.8 - 0.08 N N 120/80 - 
4 CN 42 F 120 32 13 1 - 0.07 N N 120//80 - 
5 CN 35 M 96 36 14.2 0.9 - 0.09 N N 110/70 - 
6 CN 38 F 102 35 13.2 1 - 0.08 N N 120/76 - 
7 CN 56 M 114 39 14 1.1 - 0.09 N N 130/80 - 
8 CN 53 F 108 34 13.6 0.9 - 0.07 N N 120/80 - 
9 CN 66 F 120 35 13.2 0.8 - 0.09 N N 130/80 - 
10 CN 68 M 116 38 13.8 1.1 - 0.08 N N 130/86 - 
11 CS 50 M 126 218 10.4 10.1 III 0.17 LVH N 150/90 1+ 
12 CS 23 M 68 72 8.8 3.8 - 0.14 N N 110/70 - 
13 CS 50 M 80 125 9.6 5.2 II 1.69 LVH HID 160/90 1+ 
14 CS 52 F 110 130 8.8 3.8 III 0.09 LVH HD 160/90 2+ 
15 CS 60 M 68 118 5.2 3.8 II 0.83 N HID 240/140 2+ 
16 CS 60 M 100 252 9.8 12.3 III 2.37 LVH HD 190/110 2+ 
17 CS 53 M 117 68 9.2 3 III 2.06 LVH HID 230/140 1+ 
18 CS 41 F 75 170 9.6 9.4 II 0.09 LVH N 170/100 1+ 
Sl. No.  
Case 
Control Age  Sex  
Blood 
Sugar  Urea Hb% Sr.Cr 
Retinopathy 
Gr CRP ECH Echo 
BP.(on 
Adm) 
Urine 
Alb 
19 CS 37 M 78 163 10.2 11 III 0.21 LVH N 200/120 2+ 
20 CS 65 F 102 75 8.4 2.8 III 0.13 LVH H 200/100 2+ 
21 CS 65 M 88 60 10.6 2.2 II 0.26 N N 140/90 - 
22 CS 42 M 82 161 7.4 3.2 II 2.13 N HID 190/120 2+ 
23 CS 65 F 73 122 8.8 4 III 2.56 N HID 200/130 3+ 
24 CS 33 F 112 98 10.9 3.2 I 0.12 N N 160/100 1+ 
25 CS 55 M 114 104 8.2 4.4 II 1.91 LVH HD 160/90 1+ 
26 CS 55 M 112 142 9 5.6 III 3.01 LVH HID 170/110 2+ 
27 CS 67 M 108 178 6.8 8.8 III 1.78 LVH HID 160/110 2+ 
28 CS 49 F 112 168 9.6 4.6 II 0.29 N D 150/100 1+ 
29 CS 54 M 108 196 8.6 8.3 III 1.09 LVH HID 170/120 2+ 
30 CS 31 F 118 178 9 8.9 II 0.13 N N 160/100 1+ 
31 CS 46 F 98 132 9.6 3.9 II 0.14 N N 170/100 1+ 
32 CS 27 M 104 154 8.8 13.8 III 2.16 LVH HID 150/120 3+ 
33 CS 52 M 108 130 8 9.1 II 0.16 N N 130/100 1+ 
34 CS 50 M 110 160 6.4 9.3 II 3.02 N ID 140/100 2+ 
35 CS 46 M 118 136 8.4 4.8 II 1.33 LVH HID 170/100 2+ 
36 CS 40 M 108 164 9.3 6.3 III 2.13 LVH HE 170/100 2+ 
37 CS 60 M 73 184 9.5 5.9 II 2.08 LVH HE 160/100 3+ 
38 CS 48 F 117 78 7 4.7 II 1.76 LVH HID 170/100 2+ 
39 CS 36 F 110 106 9.8 6.8 II 0.3 LVH N 150/100 1+ 
Sl. No.  
Case 
Control Age  Sex  
Blood 
Sugar  Urea Hb% Sr.Cr 
Retinopathy 
Gr CRP ECH Echo 
BP.(on 
Adm) 
Urine 
Alb 
40 CS 45 M 96 176 8.6 8.8 II 1.83 LVH HD 170/100 1+ 
41 CS 53 M 104 98 9.6 4.2 I 1.57 LVH HE 150/100 1+ 
42 CS 48 F 112 94 9.8 6.2 II 0.26 N N 140/100 2+ 
43 CS 53 M 118 124 8.2 6.8 II 2.11 LVH HD 160/110 2+ 
44 CS 42 F 87 242 5.8 9.1 III 2.07 LVH HD 170/100 2+ 
45 CS 40 F 98 163 6.8 7.8 II 2.23 LVH HED 150/100 1+ 
46 CS 54 M 96 205 7.2 7.6 II 2.71 LVH HED 160/100 1+ 
47 CS 44 F 96 154 9.2 6.8 II 0.12 N N 150/100 1+ 
48 CS 38 M 118 120 7.8 4.3 I 0.26 LVH N 160/100 2+ 
49 CS 58 M 119 103 8.6 4.5 II 1.66 LVH HD 180/100 1+ 
50 CS 46 M 108 168 10.2 6.8 II 0.13 N N 160/100 1+ 
51 CS 51 M 118 204 9.6 11.3 III 1.95 LVH HID 170/120 1+ 
52 CS 56 M 98 146 10.4 5.6 II 0.16 N N 160/100 1+ 
 
 
CN – control  
CS - Case 
 
ECG              Echo     
 
 N- Within 
normal 
limits                  N- Normal LV function  
 
 H - LVH                  I - Ischaemic changes (Wall motion anomaly / Global hypokinesia) 
 
 
                 D - LV Dysfunction   
 
 
                 H - LVH    
 
 
                E - Pericardial Effusion  
 
PROFORMA 
(CRP in CRF with cardiovascular complications) 
Name :       IP.No: 
Age/Sex: 
Address:  
Admitted for:   duration  
Chest pain  Y/N    Past History 
Palpitation   Y/N     HT 
Dyspnoea   Y/N     DM 
Pedal oedema  Y/N     P.TB 
Others        IHD 
        Others  
Personal History  Smoking  Y/N  Alcohol Y/N 
Family History 
Vitals (on adm) PR  / mt  BP  / mmHg RR /mt temp 
CVS 
RS 
ABD/  
CNS 
Investigations  
Urine ALB -   Sug  Dep  spot PCR (Pr  : Cr   ) 
Blood – TC  DC-P:  L: M: E  Hb% 
Blood sugar  Urea  CR Electrolytes  Na+ K+    Cl-  HCo3-ECG 
ECHO 
USG Abd     hs-CRP -  
Ophthalmology  
Others 
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